StockDocs
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
LFCR

Lifecore Biomedical, Inc.

LFCR Nasdaq Pharmaceutical Preparations EDGAR ↗
$4.39
-0.03 -0.68%

Key statistics

from XBRL data in SEC filings
Market cap
$165M
Revenue (TTM)
$129M
Net income (TTM)
-$38.7M
EPS (TTM)
$-1.27
P/E ratio
Dividend yield
Free cash flow
-$13.6M
Cash
$20.8M
Total assets
$225M
Gross margin
31.3%
52-week range
$3.63 – $8.98

Recent SEC filings

40 most recent
Annual, quarterly & current reports
8-K Regulation FD disclosure Jul 2, 2026 8-K Director or officer change; Shareholder vote results Jun 5, 2026 10-Q Quarter ended 2026-03-31 May 6, 2026 8-K Results of operations (earnings release); Regulation FD disclosure May 6, 2026 8-K Results of operations (earnings release); Regulation FD disclosure Mar 16, 2026 8-K Item 5.08 Mar 5, 2026 8-K Director or officer change Jan 16, 2026 8-K Regulation FD disclosure Nov 17, 2025 10-Q Quarter ended 2025-09-30 Nov 6, 2025 8-K Results of operations (earnings release); Regulation FD disclosure Nov 6, 2025 8-K Shareholder vote results Oct 31, 2025 8-K Director or officer change Sep 26, 2025 8-K Changed accountants Aug 18, 2025 8-K Regulation FD disclosure Aug 12, 2025 10-K Fiscal year ended 2025-05-25 Aug 7, 2025 8-K Results of operations (earnings release) Aug 7, 2025 8-K Director or officer change Jul 18, 2025 8-K Director or officer change Apr 16, 2025 8-K Shareholder vote results Apr 10, 2025 10-Q Quarter ended 2025-02-23 Apr 3, 2025 8-K Results of operations (earnings release); Regulation FD disclosure Apr 3, 2025 8-K Other events Jan 17, 2025 8-K Regulation FD disclosure Jan 7, 2025 10-Q Quarter ended 2024-11-24 Jan 2, 2025 8-K Results of operations (earnings release); Regulation FD disclosure Jan 2, 2025 8-K Entered a material agreement; Regulation FD disclosure Nov 26, 2024 8-K Regulation FD disclosure Nov 21, 2024 8-K Shareholder vote results Nov 8, 2024 10-Q Quarter ended 2024-08-25 Oct 4, 2024 8-K Entered a material agreement; Results of operations (earnings release); Unregistered sale of equity; Regulation FD disclosure Oct 4, 2024 8-K Director or officer change; Item 5.08 Sep 23, 2024 8-K Other events Sep 12, 2024 8-K Unregistered sale of equity; Director or officer change; Regulation FD disclosure Aug 29, 2024 8-K Results of operations (earnings release) Aug 26, 2024 10-K Fiscal year ended 2024-05-26 Aug 26, 2024 8-K Modified rights of security holders; Director or officer change; Amended charter or bylaws; Shareholder vote results Aug 21, 2024 10-Q Quarter ended 2024-02-25 Aug 9, 2024 10-Q Quarter ended 2023-11-26 Aug 9, 2024 10-Q Quarter ended 2023-08-27 Aug 9, 2024 8-K Director or officer change Jul 24, 2024